Faeth Therapeutics, Inc. General and Administrative Expense
Faeth Therapeutics, Inc. (FTH) reported General and Administrative Expense of $9.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-04
- Faeth Therapeutics, Inc. general and administrative expense for the quarter ending 2026-06-30 was $9.21M, a 244.37% increase year-over-year.
- Faeth Therapeutics, Inc. general and administrative expense for the quarter ending 2026-03-31 was $19.71M, a 455.45% increase year-over-year.
- Faeth Therapeutics, Inc. general and administrative expense for the quarter ending 2025-12-31 was $2.79M, a 1.52% decline year-over-year.
- Faeth Therapeutics, Inc. general and administrative expense for the quarter ending 2025-09-30 was $2.31M, a 27.34% decline year-over-year.
- Faeth Therapeutics, Inc. general and administrative expense for fiscal 2025 was $11.33M, a 13.10% decline from fiscal 2024.
- Faeth Therapeutics, Inc. general and administrative expense for fiscal 2024 was $13.04M, a 30.53% decline from fiscal 2023.
- Faeth Therapeutics, Inc. general and administrative expense for fiscal 2023 was $18.77M, a 5.25% decline from fiscal 2022.
- Faeth Therapeutics, Inc. general and administrative expense for fiscal 2022 was $19.80M, a 25.19% increase from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.21M 10-Q · filed 2026-08-04 | $28.92M 10-Q · filed 2026-08-04 | $31.71M derived: sum of 3 quarters · filed 2026-08-04 | $34.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $19.71M 10-Q · filed 2026-05-15 | $22.50M derived: sum of 2 quarters · filed 2026-05-15 | $24.82M derived: sum of 3 quarters · filed 2026-05-15 | $27.49M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.11M derived: sum of 2 quarters · filed 2026-03-30 | $7.78M derived: sum of 3 quarters · filed 2026-08-04 | $11.33M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.31M 10-Q · filed 2025-11-14 | $4.99M derived: sum of 2 quarters · filed 2026-08-04 | $8.54M 10-Q · filed 2025-11-14 | $11.37M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $2.67M 10-Q · filed 2026-08-04 | $6.22M 10-Q · filed 2026-08-04 | $9.06M derived: sum of 3 quarters · filed 2026-08-04 | $12.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.55M 10-Q · filed 2026-05-15 | $6.38M derived: sum of 2 quarters · filed 2026-05-15 | $9.57M derived: sum of 3 quarters · filed 2026-05-15 | $12.77M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.02M derived: sum of 2 quarters · filed 2026-03-30 | $9.22M derived: sum of 3 quarters · filed 2026-03-30 | $13.04M 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.19M 10-Q · filed 2025-11-14 | $6.39M derived: sum of 2 quarters · filed 2025-11-14 | $10.20M 10-Q · filed 2025-11-14 | $13.85M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.20M 10-Q · filed 2025-08-05 | $7.02M 10-Q · filed 2025-08-05 | $10.66M derived: sum of 3 quarters · filed 2025-08-05 | $14.58M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $3.81M 10-Q · filed 2025-05-06 | $7.46M derived: sum of 2 quarters · filed 2025-05-06 | $11.38M derived: sum of 3 quarters · filed 2025-05-06 | $16.77M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $7.57M derived: sum of 2 quarters · filed 2025-03-28 | $12.96M derived: sum of 3 quarters · filed 2025-03-28 | $18.77M 10-K · filed 2025-03-28 |
| 2023-09-30 | $3.92M 10-Q · filed 2024-11-14 | $9.31M derived: sum of 2 quarters · filed 2024-11-14 | $15.12M 10-Q · filed 2024-11-14 | $20.82M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $5.39M 10-Q · filed 2024-08-06 | $11.20M 10-Q · filed 2024-08-06 | $16.90M derived: sum of 3 quarters · filed 2024-08-06 | $21.65M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $5.80M 10-Q · filed 2024-05-09 | $11.51M derived: sum of 2 quarters · filed 2024-05-09 | $16.26M derived: sum of 3 quarters · filed 2024-05-09 | $20.58M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $10.45M derived: sum of 2 quarters · filed 2024-02-29 | $14.77M derived: sum of 3 quarters · filed 2024-02-29 | $19.80M 10-K · filed 2024-02-29 |
| 2022-09-30 | $4.75M 10-Q · filed 2023-11-07 | $9.07M derived: sum of 2 quarters · filed 2023-11-07 | $14.10M 10-Q · filed 2023-11-07 | $17.56M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $4.32M 10-Q · filed 2023-08-03 | $9.35M 10-Q · filed 2023-08-03 | $12.81M derived: sum of 3 quarters · filed 2023-08-03 | $16.68M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $5.03M 10-Q · filed 2023-05-09 | $8.49M derived: sum of 2 quarters · filed 2023-05-09 | $12.36M derived: sum of 3 quarters · filed 2023-05-09 | $16.25M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $7.33M derived: sum of 2 quarters · filed 2023-03-29 | $11.22M derived: sum of 3 quarters · filed 2023-03-29 | $15.82M 10-K · filed 2023-03-29 |
| 2021-09-30 | $3.87M 10-Q · filed 2022-11-08 | $7.76M derived: sum of 2 quarters · filed 2022-11-08 | $12.36M 10-Q · filed 2022-11-08 | $14.88M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $3.89M 10-Q · filed 2022-08-09 | $8.49M 10-Q · filed 2022-08-09 | $11.01M derived: sum of 3 quarters · filed 2022-08-09 | $12.80M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $4.60M 10-Q · filed 2022-05-10 | $7.13M derived: sum of 2 quarters · filed 2022-05-10 | $8.91M derived: sum of 3 quarters · filed 2022-05-10 | $10.22M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $4.31M derived: sum of 2 quarters · filed 2022-03-15 | $5.62M derived: sum of 3 quarters · filed 2022-03-15 | $7.53M 10-K · filed 2022-03-15 |
| 2020-09-30 | $1.79M 10-Q · filed 2021-11-10 | $3.10M derived: sum of 2 quarters · filed 2021-11-10 | $5.01M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.31M 10-Q · filed 2021-08-11 | $3.22M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $1.91M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |